drugset / Trial / NCT01797432

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432

Phase 2 Completed 14 enrolled University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the AA process and promoting hair regrowth. Furthermore, the combination of Restylane® with IL triamcinolone acetonide injections may prevent a common side effect, atrophy. With the prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone acetonide for longer periods of time, patients may see a better clinical response for a longer period of time. Quality of life may improve as the number of clinic visits decreases as would the number of IL corticosteroid injections.

Timeline

Start
2009-03
Primary completion
2014-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 4 ml Other

Indications